Engineered immune cells take on childhood cancers in first human test

NCT ID NCT03618381

Ongoing Disease control Sponsor: Seattle Children's Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests a new type of immunotherapy for children and young adults with solid tumors that have not responded to standard treatments. The therapy uses the patient's own immune cells (T cells) that are genetically modified to recognize and attack cancer cells carrying a protein called EGFR. The study will enroll 44 participants to evaluate safety, find the best dose, and see if the cells can shrink tumors. Some participants will receive cells that also target a second protein (CD19) to help the immune cells work longer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: EGFR806 CAR T cells (genetically modified immune cells)
What this could lead to: If successful, this could point toward a new treatment option for children and young adults with hard-to-treat solid tumors that have come back or not responded to standard therapy.
What could go wrong: This is an early Phase 1 trial with only 44 participants, so it is primarily testing safety and dosing. The treatment may not shrink tumors, and there are risks of serious side effects like cytokine release syndrome.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

carcinoma childhood neoplasm clear cell sarcoma desmoplastic small round cell tumor Ewing sarcoma germ cell tumor hepatoblastoma malignant peripheral nerve sheath tumor Neoplasms, Germ Cell and Embryonal neuroblastoma neurofibrosarcoma osteosarcoma retinoblastoma rhabdoid tumor rhabdomyosarcoma sarcoma soft tissue sarcoma synovial sarcoma Wilms tumor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARCINOMA CLEAR CELL SARCOMA DESMOPLASTIC SMALL ROUND CELL TUMOR EWING SARCOMA GERM CELL TUMOR HEPATOBLASTOMA MALIGNANT PERIPHERAL NERVE SHEATH TUMORS NEUROBLASTOMA OSTEOSARCOMA PEDIATRIC SOLID TUMOR RETINOBLASTOMA RHABDOID TUMOR RHABDOMYOSARCOMA SOFT TISSUE SARCOMA SYNOVIAL SARCOMA WILMS TUMOR

Engineered immune cells take on childhood cancers in first human test

Summary

What this could mean

Get notified about this study

Conditions

As listed by the trial registrant

Contacts and locations

Locations

More trials for these conditions